查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1435148

肥胖药物市场：依治疗类型、最终用途划分 - 2024-2030 年全球预测

Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), End-use (Ambulatory Surgical Centers, Hospitals, Specialty Clinics) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年肥胖药物市场规模为99.8亿美元，2024年预计将达108.1亿美元，2030年将达176亿美元，复合年增长率为8.44%。

全球肥胖药物市场

主要市场统计
基准年[2023] 99.8亿美元
预测年份 [2024] 108.1亿美元
预测年份 [2030] 176亿美元
复合年增长率（%） 8.44%
肥胖治疗药物市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估肥胖药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对肥胖药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-肥胖治疗药物市场的市场规模与预测是多少？

2-在肥胖药物市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3-肥胖治疗药物市场的技术趋势和法律规范是什么？

4-肥胖药物市场主要供应商的市场占有率是多少？

5-进入肥胖药物市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肥胖及相关疾病的发生率增加
      • 由于缺乏运动而导致久坐的生活方式增加
      • 新型抗肥胖药物介绍
    • 抑制因素
      • 肥胖药物副作用的风险（例如精神障碍和中风）
    • 机会
      • 正在进行的临床试验和研发活动
      • 与临床显着减重相关的药物标靶数量不断增加
    • 任务
      • 体重管理知识有限
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章依治疗类型分類的肥胖药物市场

  • 药品
    • 安非他酮-纳曲酮
    • Liraglutide
    • 奥利法斯特
    • 芬特明-托吡酯
    • Semaglutide
  • 治疗方法
    • 可调式胃束带
    • 内视镜袖状胃成形术
    • 胃绕道手术

第七章肥胖药物市场：依最终用途

  • 门诊手术中心
  • 医院
  • 专科诊所

第八章北美和南美肥胖药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区肥胖药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲肥胖药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第12章竞争产品组合

  • 主要公司简介
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Currax Pharmaceuticals LLC
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Merck & Co., Inc.
    • Norgine BV
    • Novartis AG
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Rhythm Pharmaceuticals, Inc.
    • SHIONOGI & Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vivus LLC
  • 主要产品系列

第十三章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-EC2E133E33FA

[180 Pages Report] The Anti-Obesity Therapeutics Market size was estimated at USD 9.98 billion in 2023 and expected to reach USD 10.81 billion in 2024, at a CAGR 8.44% to reach USD 17.60 billion by 2030.

Global Anti-Obesity Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 9.98 billion
Estimated Year [2024] USD 10.81 billion
Forecast Year [2030] USD 17.60 billion
CAGR (%) 8.44%
Anti-Obesity Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Obesity Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Obesity Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus LLC.

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • Medications
      • Bupropion-naltrexone
      • Liraglutide
      • Orlistat
      • Phentermine-topiramate
      • Semaglutide
    • Treatments
      • Adjustable Gastric Banding
      • Endoscopic Sleeve Gastroplasty
      • Gastric Bypass Surgery
  • End-use
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anti-Obesity Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Obesity Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Anti-Obesity Therapeutics Market?

4. What is the market share of the leading vendors in the Anti-Obesity Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Anti-Obesity Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anti-Obesity Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of obesity and related disorder
      • 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
      • 5.1.1.3. Introduction of novel anti-obesity drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing clinical trials and research & development activities
      • 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
    • 5.1.4. Challenges
      • 5.1.4.1. Limited of knowledge regarding weight management
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anti-Obesity Therapeutics Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.3.1. Bupropion-naltrexone
    • 6.3.2. Liraglutide
    • 6.3.3. Orlistat
    • 6.3.4. Phentermine-topiramate
    • 6.3.5. Semaglutide
  • 6.3. Treatments
    • 6.4.1. Adjustable Gastric Banding
    • 6.4.2. Endoscopic Sleeve Gastroplasty
    • 6.4.3. Gastric Bypass Surgery

7. Anti-Obesity Therapeutics Market, by End-use

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Hospitals
  • 7.4. Specialty Clinics

8. Americas Anti-Obesity Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anti-Obesity Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Boehringer Ingelheim International GmbH
    • 12.1.2. Bristol-Myers Squibb Company
    • 12.1.3. Currax Pharmaceuticals LLC
    • 12.1.4. Eisai Co., Ltd.
    • 12.1.5. Eli Lilly and Company
    • 12.1.6. F. Hoffmann-La Roche Ltd.
    • 12.1.7. GlaxoSmithKline PLC
    • 12.1.8. Merck & Co., Inc.
    • 12.1.9. Norgine B.V.
    • 12.1.10. Novartis AG
    • 12.1.11. Novo Nordisk A/S
    • 12.1.12. Pfizer Inc.
    • 12.1.13. Rhythm Pharmaceuticals, Inc.
    • 12.1.14. SHIONOGI & Co., Ltd.
    • 12.1.15. Takeda Pharmaceutical Company Limited
    • 12.1.16. Vivus LLC
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTI-OBESITY THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 10. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 8. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 15. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 19. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 191. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. ANTI-OBESITY THERAPEUTICS MARKET LICENSE & PRICING